The Board of Directors of Strides Pharma Science Limited, at their meeting held on May 18, 2026, considered and recommended the appointment of M/s. Deloitte Haskins & Sells LLP, Chartered Accountants, as the company's Statutory Auditors for a term of five consecutive years. The recommendation was made based on the Audit Committee's advice and was disclosed to the stock exchanges pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The board meeting commenced at 12:30 hrs IST and concluded at 14:15 hrs IST.

Reason for Auditor Rotation

The proposed change in statutory auditors is driven by the mandatory rotation requirement under applicable regulations. M/s. B S R & Co. LLP, Chartered Accountants (Firm Registration No. 101248W/W-100022), the existing Statutory Auditors of the company, will complete their second term of five consecutive years upon conclusion of the 36th AGM to be held in the year 2027. As a result, the board has recommended the appointment of a new audit firm in compliance with statutory rotation norms.

Key Details of the Proposed Appointment

The following table summarises the key parameters of the proposed auditor appointment:

Profile of the Incoming Auditor

Deloitte Haskins & Sells LLP has a well-established presence in India. Key details of the firm are as follows:

• Constituted: Deloitte Haskins & Sells, Mumbai was constituted in 1997.
• Converted to LLP: The firm was converted to a Limited Liability Partnership with effect from November 20, 2013.
• ICAI Registration: Registered with the Institute of Chartered Accountants of India (Registration No. 117366W/W-100018).
• Network Affiliation: Part of Deloitte Haskins & Sells & Affiliates, being the Network of Firms registered with the ICAI.
• Registered Office: One International Center, Tower 3, 31st Floor, Senapati Bapat Marg, Elphinstone Road (West), Mumbai - 400013, Maharashtra, India.

Shareholder Approval Process

The proposed appointment of M/s. Deloitte Haskins & Sells LLP is subject to the approval of the shareholders of Strides Pharma Science Limited. Shareholder approval for this matter is to be sought during the 36th AGM, scheduled to be held in the year 2027. The disclosure was made in accordance with Regulation 30 of the SEBI Listing Regulations read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026. The information has also been made available on the company's website at www.strides.com .

Strides Pharma Science has outlined a clear revenue target for its North America business, aiming to reach $400M in the region by FY28, even as it acknowledges existing challenges in the market. The company's strategic outlook points to a phased recovery and growth trajectory, with key milestones anchored around the second half of FY27.

North America Growth Roadmap

Strides Pharma Science has communicated that despite the current headwinds facing its North America operations, the company remains committed to scaling its presence in the region. The $400M revenue target for FY28 underscores the company's confidence in its long-term growth strategy for this geography.

The following table summarizes the key strategic milestones outlined by the company:

Sandoz Partnership and Near-Term Outlook

A notable development in Strides Pharma Science's North America strategy is the expected contribution from Sandoz, which the company has announced will begin from H2 FY27 onwards. This partnership is positioned as a meaningful driver of the company's revenue ramp-up in the region leading up to the FY28 target.

The company has also indicated that broader growth in North America is anticipated to resume by H2 FY27, suggesting that the near-term period may continue to reflect the current challenges before a more meaningful recovery takes shape in the latter half of FY27.